leadf
logo-loader
viewInvitrocue Ltd

Invitrocue and Genome Institute of Singapore to develop in vitro cancer models

The joint laboratory will leverage Invitrocue’s capabilities in cell-based products.

A newspaper heading about cancer
The innovation laboratory will focus on four oncology indications

Invitrocue (ASX:IVQ) has established a joint innovation laboratory with the Genome Institute of Singapore to develop cancer organoids to better guide clinical decision in cancer management.

Invitrocue is a provider of bio-analytic solutions including in vitro cell-based testing technologies and image analytics software for use in digital pathology.

The Genome Institute of Singapore (GIS) is a government supported initiative which seeks to use genomic sciences to achieve significant improvements in human health.

The GIS- Invitrocue joint laboratory aims to develop tumour models to enhance decision-making for clinicians, and enable them to personalise treatment to help patients manage the disease.

The laboratory will focus on four oncology indications which include head and neck cancer, colorectal cancer, liver cancer and triple negative breast cancer.

As one of the world’s leading centres for genomic discovery, GIS pursues the integration of technology, genetics and biology towards the goal of individualised medicine.

The joint laboratory will leverage GIS’ expertise in genomics, oncology and organoid biology, and Invitrocue’s capabilities in developing cell-based products and services for commercialisation.

Over time the laboratory will employ up to 20 personnel in various scientific and technical roles.

Invitrocue has also partnered with groups in Australia, such as the Garvan Institute of Medical Research to scale its efforts.

Quick facts: Invitrocue Ltd

Price: - AUD

ASX:IVQ
Market: ASX
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Invitrocue Ltd named herein, including the promotion by the Company of Invitrocue Ltd in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read